Sign in Subscribe
Cancer research

Lower Cancer Risk Linked to Popular Obesity Drugs

Strategic Insights

— 1 min read

A study involving 170,000 patient records found that individuals with diabetes who took GLP-1 receptor agonists, medications commonly used to treat obesity, had a lower risk of developing obesity-related cancers compared to those who took a different type of diabetes drug. The analysis revealed a 7% lower risk of obesity-related cancer and an 8% lower risk of death from any cause in the GLP-1 group after four years.

Key Takeaways:

  • The study, released by the American Society of Clinical Oncology, analyzed data from 43 U.S. health systems to compare the effects of GLP-1 receptor agonists and another type of diabetes drug, sitagliptin, on individuals with obesity and diabetes.
  • There were 2,501 new cases of obesity-related cancer in the GLP-1 group, which is 7% lower than the 2,671 cases in the group taking sitagliptin.
  • The risk reduction was evident in women but not statistically significant in men, with Mavromatis attributing this difference to potential variations in blood drug concentration, weight loss, metabolism, or hormones.
  • Dr. Ernest Hawk of MD Anderson Cancer Center emphasized the need for further research on this potential connection, stating, "This is a call to scientists and clinical investigators to do more work in this area to really prove or disprove this."
  • GLP-1 receptor agonists, used for diabetes treatment and some obesity treatment, mimic hormones to regulate appetite and feelings of fullness, with potential side effects including nausea and stomach pain.
  • The study's findings suggest a potential role for these medications in reducing the risk of obesity-related cancers, which number over a dozen.

Statistics:

  • 170,000 patient records were included in the study's analysis.
  • 7% lower risk of developing an obesity-related cancer in individuals taking GLP-1 receptor agonists.
  • 8% lower risk of death from any cause in the GLP-1 group after four years.
  • 2,501 new cases of obesity-related cancer in the GLP-1 group.
  • 2,671 cases of obesity-related cancer in the group taking sitagliptin.

Sources:

  • The American Society of Clinical Oncology
  • New York University's Grossman School of Medicine
  • MD Anderson Cancer Center in Houston
  • National Institutes of Health
  • The Associated Press Health and Science Department
  • Howard Hughes Medical Institute's Science and Educational Media Group
  • Robert Wood Johnson Foundation

Read more